# Cognitive Symptom Trajectories among Forensic Inpatients Diagnosed with Psychotic Disorders

CSU Student Research Competition May 4<sup>th</sup>-5<sup>th</sup>, 2018

By: Jennifer Hatch

Mentor: Danielle Burchett, PhD

California State University, Monterey Bay

Collaborator: David M. Glassmire, PhD

Patton State Hospital



#### Disclosures

The statements and opinions expressed are those of the authors and do not constitute the official views or the official policy of DSH-Patton, the California Department of State Hospitals, or the State of California.

#### **Funding:**

- Undergraduate Research Opportunities Center (UROC)
- University of Minnesota Press: Test Division

#### Overview of Psychotic Disorders

Schizophrenia, Schizoaffective

Characterized by Hallucinations & Delusions

1% of U.S. population

#### Clinicians need accurate information for:

Assessment

Understanding patient experience

**Treatment** 

#### Two-Part Cross-Sectional Study

Overall Cognitive Symptom Trajectory

Impact of Comorbid Mood Disorders

#### Cognitive Symptoms



(Dickinson, & Harvey, 2009; Garcia, Viechtbauer, Simons, van Os, & Krabbendam, 2009; Keefe, & Harvey, 2012)

### Research Question I



What is the trajectory of cognitive symptoms for patients as they age?

### Research Question 2



How would comorbid mood disorders impact cognitive symptom severity?


### Research So Far




Follow Patients over Time

Compare across Age Groups

#### Neurodevelopmental Trajectory Model







(Irani et al., 2011; Herold, Schmid, Lässer, Seidl, & Schröder, 2017)

### Research Question 1




What is the trajectory of cognitive symptoms for patients as they age?






### Research Question 1

#### Hypotheses: Neurodegenerative Trajectory









Anxiety

Depression

Mania


### Research Question 2


How would comorbid mood disorders impact cognitive symptom severity?

#### **Exploratory Analyses:**

Due to the limited and mixed research, we could not form formal hypotheses

#### Method





- Not Guilty by Reason of Insanity
- Mentally Disordered
  Offender
- OIncompetent to Stand Trial
- OMentally Disordered Sex
  Offender
- OPrison Transfer
- **O**Other

#### Measures

Minnesota Multiphasic Personality Inventory –2 Restructured Form (MMPI-2-RF)

VRIN-r COG

# Variable Response Inconsistency – Revised (VRIN-r)


Reading Comprehension Problems

Uncooperative

VRIN-r

Cognitive Problems

**Fatigue** 



# Variable Response Inconsistency – Revised (VRIN-r)


Reading Comprehension Problems

Uncooperative


VRIN-r

Cognitive Problems


Fatigue


























### Procedures: RQ I

Young (18-34 years)


Middle (35-49 years)

Older (≥ 50 years)

Removed Invalid Protocols for COG analyses



Analysis of Variance (ANOVA) to compare mean scores across 3 groups



### Procedures: RQ 2



Schizophrenia (Sz)

Sz Only

Sz + Mood

Young

Young


Middle

Middle

Older



Independent Samples t-tests to compare mean scores across 2 groups





Sz Only

Sz Mood

Young

Young

Middle

Middle

Older



Sz Only

Sz Mood

Young

Young

Middle

Middle

Older



Sz Only

Sz Mood

Young

Young

Middle

Middle


Older


#### Results

### Research Question 1




What is the trajectory of cognitive symptoms for patients as they age?






### Research Question 1

#### Hypotheses: Neurodegenerative Trajectory






#### VRIN-r ANOVA Results






### VRIN-r ANOVA Results





No significant differences were found

$$F(2, 705) = 1.52, p = .22$$




59.94

Middle (n = 338)

59.36





57.12





# COG ANOVA Results

No significant differences were found


$$F(2, 456) = .69, p = .51$$




(n = 95)


# Research Question 1

### Hypotheses: Neurodegenerative Trajectory





# Research Question 1 Results: Neither Trajectory



# Research Question 2

How would comorbid mood disorders impact cognitive symptom severity?


#### **Exploratory Analyses:**

Due to the limited and mixed research, we could not form formal hypotheses

# VRIN-r Independent Samples t-test Results




Sz Only Sz + Mood



#### VRIN-r Independent Samples t-test Results




Sz Only Sz + Mood



#### VRIN-r Independent Samples t-test Results






## COG Independent Samples t-test Results




Sz Only Sz + Mood



# COG Independent Samples t-test Results




Sz Only Sz + Mood



### COG Independent Samples t-test Results



Sz Only Sz + Mood No significant differences



# Research Question 2



#### **Results:**

Comorbid mood disorders did not significantly impact cognitive symptom severity.

#### Conclusions & Future Directions

# Research Question I



Patients may not experience increased cognitive symptom severity as they age

# Research Question 2



Having mood disorders may not impact cognitive dysfunction

#### How does this inform Clinicians?

Clinicians may not have to worry about cognitive symptoms worsening over time due to age

Comorbid mood disorders may not impact the level of treatment needed for cognitive symptoms

#### Future Directions in Research

Use more direct and specific measures of cognitive symptoms

Among larger samples and younger age groups

Controlling for additional variables

#### Acknowledgements

- Mentor: Danielle Burchett, PhD Department of Psychology
- Collaborator: David M. Glassmire, PhD, APPB





#### References

American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders: DSM-5(5th ed.). Arlington, VA: American Psychiatric Association.

Ben-Porath, Y. S. & Tellegen, A. (2008/2011). MMPI-2-RF Manual for Administration, Scoring, and Interpretation. Minneapolis: University of Minnesota Press.

Ben-Porath, Y.S. (2012). Interpreting the MMPI -2-RF. Minneapolis: University of Minnesota Press.

Bora, E., Yucel, M., & Pantelis, C. (2009). Cognitive functioning in schizophrenia, schizoaffective disorder and affective psychosis: meta-analytic study. The British Journal of Psychiatry, 195(6), 475-482. doi:

10.1192/bjp.bp.108.055731

Burchett, D. & Ben-Porath, Y. S. (2010) The impact of overreporting on MMPI-2-RF substantive scale score validity. *Assessment*, 17(4), 497-516. doi: 10.1177/1073191110378972

Depp. C. A., Moore, D. J., Sitzer, Palmer, B. W., Eyler, L. T., Roesch, S.,... Jeste, D. V. (2007). Neurocognitive impairment in middle-aged and older adults with bipolar disorders: Comparison to schizophrenia and normal comparison subjects. Journal of Affective Disorders, 101(1), 201-209. doi:

10.1016/j.jad.2006.11.022

Fazel, S. & Danesh, J. (2002). Serious mental disorder in 23 000 prisoners: a systematic review of 62 surveys. *The Lancet*, *359*(9306), 545-550. doi: 10.1016/S0140-6736(02)07740-1

#### References

Fucetola, R., Seidman, L. J., Kremen, W. S., Faraone, S. V., Goldstein, J. M., & Tsuang, M. T. (2000). Age and neuropsychologic function in schizophrenia: A decline in executive abilities beyond that observed in healthy volunteers. *Biological Psychology, 48*(2), 137-146. doi: 10.1016/S0006-3223(00)00240-7 Heaton, R. K., Gladsjo, J. A., Palmer, B. W., Kuck, J., Marcotte, T. D., & Jeste, D. V. (2001). Stability and course of neuropsychological deficits in schizophrenia. *Archives of General Psychiatry, 58*(1), 24-32. doi: 10.1001/archpsyc.58.1.24

Herold, C. J., Schmid, L. A., Lasser, M. M., Seidl, U., & Schroder, J. (2017). Cognitive performance in patients with chronic schizophrenia across the lifespan. *The Journal of Gerontopsychology and Geriatric Psychiatry*, 30(1), 35-44. doi: 10.1024/1662-9647/a000164

Hulshoff Pol, H. E., Schnack, H. G., Bertens, M. G., van Haren, N. E., van der Tweel, I., Staal W. G., Baaré, W. F., & Kahn, R. S. (2002). Volume changes in gray matter in patients with schizophrenia. *The American journal of Psychiatry*, 159(2), 244-250. doi: 10.1176/appi.ajp.159.2.244

Irani, F., Kalkstein, S., Moberg, E. A., & Moberg, P. J. (2011). Neuropsychological performance in older patients with schizophrenia: A meta-analysis of cross-sectional and longitudinal studies. *Schizophrenia Bulletin*, *37*(6), 1318-1326. doi: 10.1093/schbul/sbq057

Kurtz, M. M. (2005). Neurocognitive impairment across the lifespan in schizophrenia: an update. *Schizophrenia research*, 74(1), 15-26. doi: 10.1016/j.schres.2004.07.005

# Thank you!

Questions?

#### DSM-IV-TR Diagnostic Codes

#### **Schizophrenia Only**

**Schizophrenia Disorders**: 295.10, 295.30, 295.40, 295.50, 295.60, 295.90

#### **Schizophrenia with Mood**

Schizoaffective Disorder: 295.70, 295.770

**Depressive/Anxiety Disorders**: 296.22, 296.24, 296.30, 296.31, 296.32, 296.34, 296.35

Bipolar Disorders: 296.00, 296.40, 296.41, 296.42, 296.43, 296.44, 296.45, 296.46, 296.50,

296.51, 296.52, 296.53, 296.54, 296.55, 296.60, 296.7, 296.70, 296.62, 296.64

#### **Excluded from Analyses:**

**Drug-Induced Psychotic Disorders**: 291.3, 291.50, 292.10, 292.11, 292.12

Psychotic Disorders due to Medical Condition: 293.81, 293.82

**Mood Disorders due to Medical Condition**: 293.83

Delusional Disorders, Brief Psychotic Disorder, Psychotic Disorder NOS: 297.10, 298.8,

298.9